Department of Health
MEDICINES CONTROL AGENCY
Market Towers 1 Nine Elms Lane London SW8 5NQ
Telephone 020 7273 0100/0546
Facsimile  020 7273 0548	.

Dear Dr Healy,    

RE: SSRIs and the risk of suicide

Thank you for your letter of 4 April 2001 and for your fax of 7 June 2001.

We have reviewed the studies that you have referenced. These provide evidence that sertraline and paroxetine may be associated with CNS activation. I would like to point out that agitation is listed as an adverse effect in the Summaries of Product Characteristics of all SSRIs.

Thank you for informing us about your lecture in Toronto and for taxing us a copy of the lecture. Your letter of 20 December enclosed posters relating to your healthy volunteer study. As discussed at our meeting in December 2000, we are very interested to receive the full report of this study and would be grateful if you would confirm when this will be available.

Your fax of 7 June outlines your views on the recent court case in the USA. The Committee on Safety of Medicines (CSM) will be considering data from volunteer studies involving SSRIs in July 2001. We would be very interested to receive any data from the recent trial in the USA that you consider would be relevant for CSM to consider.

Yours sincerely
Dr June Raine
Director of Post-Licensing

CLICK HERE TO READ ON
Or HERE for full index of this correspondence 

	Contents page
	What's New?